CRChava L. Ramspek

Chava L. Ramspek

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Chava L. Ramspek has a total of 94 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Dealing with an uncertain future: a survey study on what patients with chronic kidney disease actually want to know

    by Jet Milders, Chava L Ramspek, Yvette Meuleman, Willem Jan W Bos, Wieneke M Michels, Wanda S Konijn, Friedo W Dekker, Merel van Diepen

    Background: Prognostic uncertainty is a recurring theme among patients with chronic kidney disease (CKD). We developed a survey to explore whether CKD patients want to know more about their future, and if so, which topics they prioritize. In addition, we explored differences between several subgroups. Methods: A survey was constructed and tested in collaboration with the Dutch Kidney Patients Association. The survey consisted of three parts: (i) demographics, (ii) considerations about the future, and (iii) prognostic information. The survey was distributed among CKD patients (all stages) through patient associations and via healthcare professionals in two Dutch hospitals. Descriptive statistics were used to summarize the results. All results were stratified by population, sex, and age. Results: A total of 163 patients (45 CKD, 26 dialysis, and 92 kidney transplantation) participated in the survey. The mean age was 63.9 (SD 12.0) and 48.5% was male. Most patients think about their future with CKD occasionally (56.4%) or often (35.0%). Nearly half of the patients (49.7%) discuss the future with their nephrologist, some (19.6%) do not but would like to, and 20 (15.3%) prefer not to. Most patients (73.6%) want more prognostic information, regardless of it being positive or negative. Key topics to receive prognostic information about were laboratory values, symptoms, and physical well-being. Dialysis patients prioritized mental over physical well-being. CKD patients without kidney replacement therapy (KRT) indicated thinking about, and discussing their future more regularly than KRT patients. Conclusions: Patients with CKD contemplate their future regularly and express interest in receiving prognostic information on a variety of topics. One in five patients currently do not discuss their future with CKD with their nephrologist, despite wanting to do so. These findings underline the need to tailor prognostic information provision to patients’ preferences, advocating more attention to this subject both in research and clinical practice.


  • Open Access

    Clinical impact of the Kidney Failure Risk Equation for vascular access planning

    by Ulrika Hahn Lundström, Chava L Ramspek, Friedo W Dekker, Merel van Diepen, Juan Jesus Carrero, Ulf Hedin, Marie Evans

    Risk-based thresholds for arteriovenous (AV) access creation has been proposed to aid vascular access planning. We aimed to assess the clinical impact of implementing the kidney failure risk equation (KFRE) for vascular access referral. 16,102 nephrology-referred chronic kidney disease (CKD) patients from the Swedish Renal Registry 2008-2018 were included. The KFRE was calculated repeatedly, and the timing was identified for when the KFRE risk exceeded several pre-defined thresholds and/or the estimated glomerular filtration rate 50% 94.5 (95% Confidence interval [CI] 94.3–94.7), followed by KFRE>40% 90.0 (95% CI 89.7–90.3), while sensitivity was highest for KFRE>30% 79.3 (95% CI 78.2–80.3) and eGFR50%, KFRE>40%, and eGFR40% over two years and KFRE>50% over 12 months when it is important to avoid the harm of possibly unnecessary surgery. In Sweden, 54% of nephrology-referred patients started hemodialysis in a central venous catheter (CVC) of which only 5% had AV access surgery >6 months before initiation. 60% of the CVC patients exceeded KFRE>40% a median of 0.8 years (interquartile range 0.4-1.5) before KRT initiation. The utility of using KFRE>40% and KFRE>50% is higher compared to the more traditionally used eGFR threshold 2 for vascular access planning.


  • External validation of risk scores to predict in-hospital mortality in patients hospitalized due to coronavirus disease 2019

    by Shermarke Hassan, Chava L. Ramspek, Barbara Ferrari, Merel van Diepen, Raffaella Rossio, Rachel Knevel, Vincenzo la Mura, Andrea Artoni, Ida Martinelli, Alessandra Bandera, et al.


  • Open Access

    Optimising Access Surgery in Senior Haemodialysis Patients (OASIS): study protocol for a multicentre randomised controlled trial

    by Boudewijn Dc Heggen, Chava L Ramspek, Koen E A van der Bogt, Michiel W de Haan, Marc H Hemmelder, Mickaël J C Hiligsmann, Magda M van Loon, Joris I Rotmans, Jan H M Tordoir, Friedo W Dekker, et al.

    Introduction Current evidence on vascular access strategies for haemodialysis patients is based on observational studies that are at high risk of selection bias. For elderly patients, autologous arteriovenous fistulas that are typically created in usual care may not be the best option because a significant proportion of fistulas either fail to mature or remain unused. In addition, long-term complications associated with arteriovenous grafts and central venous catheters may be less relevant when considering the limited life expectancy of these patients. Therefore, we designed the Optimising Access Surgery in Senior Haemodialysis Patients (OASIS) trial to determine the best strategy for vascular access creation in elderly haemodialysis patients. Methods and analysis OASIS is a multicentre randomised controlled trial with an equal participant allocation in three treatment arms. Patients aged 70 years or older who are expected to initiate haemodialysis treatment in the next 6 months or who have started haemodialysis urgently with a catheter will be enrolled. To detect and exclude patients with an unusually long life expectancy, we will use a previously published mortality prediction model after external validation. Participants allocated to the usual care arm will be treated according to current guidelines on vascular access creation and will undergo fistula creation. Participants allocated to one of the two intervention arms will undergo graft placement or catheter insertion. The primary outcome is the number of access-related interventions required for each patient-year of haemodialysis treatment. We will enrol 195 patients to have sufficient statistical power to detect an absolute decrease of 0.80 interventions per year. Ethics and dissemination Because of clinical equipoise, we believe it is justified to randomly allocate elderly patients to the different vascular access strategies. The study was approved by an accredited medical ethics review committee. The results will be disseminated through peer-reviewed publications and will be implemented in clinical practice guidelines. Trial registration number NL7933. Protocol version and date V.5, 25 February 2021.


  • Open Access

    Lessons learnt when accounting for competing events in the external validation of time-to-event prognostic models

    by Chava L Ramspek, Lucy Teece, Kym I E Snell, Marie Evans, Richard D Riley, Maarten van Smeden, Nan van Geloven, Merel van Diepen

    Background: External validation of prognostic models is necessary to assess the accuracy and generalizability of the model to new patients. If models are validated in a setting in which competing events occur, these competing risks should be accounted for when comparing predicted risks to observed outcomes. Methods: We discuss existing measures of calibration and discrimination that incorporate competing events for time-to-event models. These methods are illustrated using a clinical-data example concerning the prediction of kidney failure in a population with advanced chronic kidney disease (CKD), using the guideline-recommended Kidney Failure Risk Equation (KFRE). The KFRE was developed using Cox regression in a diverse population of CKD patients and has been proposed for use in patients with advanced CKD in whom death is a frequent competing event. Results: When validating the 5-year KFRE with methods that account for competing events, it becomes apparent that the 5-year KFRE considerably overestimates the real-world risk of kidney failure. The absolute overestimation was 10%age points on average and 29%age points in older high-risk patients. Conclusions: It is crucial that competing events are accounted for during external validation to provide a more reliable assessment the performance of a model in clinical settings in which competing risks occur.


  • Open Access

    Prediction or causality? A scoping review of their conflation within current observational research

    by Chava L. Ramspek, Ewout W. Steyerberg, Richard D. Riley, Frits R. Rosendaal, Olaf M. Dekkers, Friedo W. Dekker, Merel van Diepen

    Etiological research aims to uncover causal effects, whilst prediction research aims to forecast an outcome with the best accuracy. Causal and prediction research usually require different methods, and yet their findings may get conflated when reported and interpreted. The aim of the current study is to quantify the frequency of conflation between etiological and prediction research, to discuss common underlying mistakes and provide recommendations on how to avoid these. Observational cohort studies published in January 2018 in the top-ranked journals of six distinct medical fields (Cardiology, Clinical Epidemiology, Clinical Neurology, General and Internal Medicine, Nephrology and Surgery) were included for the current scoping review. Data on conflation was extracted through signaling questions. In total, 180 studies were included. Overall, 26% (n = 46) contained conflation between etiology and prediction. The frequency of conflation varied across medical field and journal impact factor. From the causal studies 22% was conflated, mainly due to the selection of covariates based on their ability to predict without taking the causal structure into account. Within prediction studies 38% was conflated, the most frequent reason was a causal interpretation of covariates included in a prediction model. Conflation of etiology and prediction is a common methodological error in observational medical research and more frequent in prediction studies. As this may lead to biased estimations and erroneous conclusions, researchers must be careful when designing, interpreting and disseminating their research to ensure this conflation is avoided.


  • Open Access

    Development and external validation study combining existing models and recent data into an up-to-date prediction model for evaluating kidneys from older deceased donors for transplantation

    by Chava L. Ramspek, Mostafa El Moumni, Eelaha Wali, Martin B.A. Heemskerk, Robert A. Pol, Meindert J. Crop, Nichon E. Jansen, Andries Hoitsma, Friedo W. Dekker, M. van Diepen, et al.


  • Kidney Failure Prediction Models: A Comprehensive External Validation Study in Patients with Advanced CKD

    by Chava L. Ramspek, Marie Evans, Christoph Wanner, Christiane Drechsler, Nicholas C. Chesnaye, Maciej Szymczak, Magdalena Krajewska, Claudia Torino, Gaetana Porto, Samantha Hayward, et al.

    Significance Statement: Most kidney failure prediction models have been developed and validated in cohorts of patients with a wide range of disease severity, without accounting for the competing risk of death. Models recommended by guidelines, currently used in the clinic, have not undergone a head-to-head comparison. This study provides a comprehensive external validation of kidney failure prediction tools in two cohorts of patients with advanced CKD, taking the competing risk of death into account. Models that predict over a longer time frame of 5 years overestimate risk due to the competing risk of death. In patients with advanced CKD, the eight-variable 2-year Kidney Failure Risk Equation is recommended for short-term predictions surrounding preparation for RRT. The 4-year Grams model, which accounts for competing risk, is most suitable for longer-term predictions. Background: Various prediction models have been developed to predict the risk of kidney failure in patients with CKD. However, guideline-recommended models have yet to be compared head to head, their validation in patients with advanced CKD is lacking, and most do not account for competing risks. Methods: To externally validate 11 existing models of kidney failure, taking the competing risk of death into account, we included patients with advanced CKD from two large cohorts: the European Quality Study (EQUAL), an ongoing European prospective, multicenter cohort study of older patients with advanced CKD, and the Swedish Renal Registry (SRR), an ongoing registry of nephrology-referred patients with CKD in Sweden. The outcome of the models was kidney failure (defined as RRT-treated ESKD). We assessed model performance with discrimination and calibration. Results: The study included 1580 patients from EQUAL and 13,489 patients from SRR. The average c statistic over the 11 validated models was 0.74 in EQUAL and 0.80 in SRR, compared with 0.89 in previous validations. Most models with longer prediction horizons overestimated the risk of kidney failure considerably. The 5-year Kidney Failure Risk Equation (KFRE) overpredicted risk by 10%–18%. The four- and eight-variable 2-year KFRE and the 4-year Grams model showed excellent calibration and good discrimination in both cohorts. Conclusions: Some existing models can accurately predict kidney failure in patients with advanced CKD. KFRE performed well for a shorter time frame (2 years), despite not accounting for competing events. Models predicting over a longer time frame (5 years) overestimated risk because of the competing risk of death. The Grams model, which accounts for the latter, is suitable for longer-term predictions (4 years).


  • Top Cited Papers
    Open Access

    External validation of prognostic models: what, why, how, when and where?

    by Chava L Ramspek, Kitty J Jager, Friedo W Dekker, Carmine Zoccali, Merel van Diepen

    Prognostic models that aim to improve the prediction of clinical events, individualized treatment and decision-making are increasingly being developed and published. However, relatively few models are externally validated and validation by independent researchers is rare. External validation is necessary to determine a prediction model’s reproducibility and generalizability to new and different patients. Various methodological considerations are important when assessing or designing an external validation study. In this article, an overview is provided of these considerations, starting with what external validation is, what types of external validation can be distinguished and why such studies are a crucial step towards the clinical implementation of accurate prediction models. Statistical analyses and interpretation of external validation results are reviewed in an intuitive manner and considerations for selecting an appropriate existing prediction model and external validation population are discussed. This study enables clinicians and researchers to gain a deeper understanding of how to interpret model validation results and how to translate these results to their own patient population.